Lakefront Biotherapeutics NV current report, Q2 FY2026

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (a Foreign Private Issuer) for the month of May 2026, specifically dated May 6, 2026. The filing incorporates by reference a press release (Exhibit 99.1) issued on the same date. The registrant files annual reports on Form 20-F.

Note: The request metadata lists "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as "Galapagos NV."

Financial Metrics

The provided filing text does not contain specific financial data. It serves as a procedural vehicle to incorporate a press release by reference. Consequently, the following metrics are not available in this document:

  • Revenue
  • Profit
  • Cash Flow
  • Margins
  • Debt and Liquidity

Material Changes

The filing text does not provide details on material changes versus prior periods. The content is limited to the administrative incorporation of an external press release.

Guidance, Outlook, and Risks

The filing text does not include management commentary, guidance, outlook, risks, or contingencies. It references quotes from Henry Gosebruch and Aaron Cox within the attached Exhibit 99.1, but the text of those quotes is not included in the provided input.

Key Facts for Investor Verification

  • Verify the actual content of the press release (Exhibit 99.1) to understand the specific corporate event or announcement triggering this filing.
  • Confirm the identity of the registrant as Galapagos NV, distinct from the metadata label "Lakefront Biotherapeutics NV."
  • Review the incorporated press release for any updates on clinical trials, partnerships, or financial results, as this Form 6-K contains no such data directly.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.